Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Paraganglioma Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

4 recruiting trials for Paraganglioma. Eligibility criteria explained in plain English.

TrialFinderData lists 4 Paraganglioma clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 / Phase 2 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by University of Pennsylvania (1), Perspective Therapeutics (1), Fundación de investigación HM (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Behavioral nudge (behavioral, 1 trial), followed by [203Pb]VMT-α-NET, [212Pb]VMT-α-NET.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
4
Total Trials
4
Recruiting Now
0
Phase 3 Trials
4
Sponsors

Track Paraganglioma trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06377033

Using the EHR to Advance Genomic Medicine Across a Diverse Health System

Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways...

Sponsor: University of PennsylvaniaEnrolling: 10001 location
RECRUITINGPhase 1 / Phase 2NCT05636618

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

This study is Phase I/IIa First-in-Human Study of \[212Pb\]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors

Sponsor: Perspective TherapeuticsEnrolling: 30019 locations
RECRUITINGPhase 1 / Phase 2NCT06607692

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the...

Study in children and adolescents of 177Lu DOTATATE (Lutathera®) combined with the PARP inhibitor olaparib for treatment of recurrent or relapsed solid tumours expressing...

Sponsor: Fundación de investigación HMEnrolling: 251 location
RECRUITINGNCT06573723

Institutional Registry of Rare Diseases

The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD)....

Sponsor: Hospital Italiano de Buenos AiresEnrolling: 3801 location

Frequently Asked Questions

There are currently 4 clinical trials for Paraganglioma, with 4 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Paraganglioma, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Paraganglioma, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.